Nivolumab/Ipilimumab Efficacy in Clear Cell RCC May Be Tied to Certain Immune-Cell Related Parameters

February 22, 2022

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Germline Testing for Lynch Syndrome: More Important Than Ever

October 04, 2020

With the emergence of several targeted treatments that have shown efficacy in individuals with germline pathogenic variants, specifically in DNA mismatch repair, the need for germline genetic testing has become even more pronounced.

Cancer and Genetic Testing: Expert Answers Common Questions

August 02, 2020

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types. While these personalized treatments are improving outcomes, navigating the landscape of genetic testing can leave patients with questions for their providers.